A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Trial details
- Registry ID
- NCT06319456
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.NCT06319456 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2027-08Estimated |
| Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).NCT06641414 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2029-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |